Drug-Induced Lung Injury (Record no. 9107)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04070nam a22004097a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240305192606.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 220830b |||||||| |||| 00| 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 981104466X |
| International Standard Book Number | 9789811044663 |
| 040 ## - CATALOGING SOURCE | |
| Transcribing agency | DLC |
| 082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.2/4 HAN |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Masayuki Hanaoka |
| 9 (RLIN) | 43554 |
| 222 ## - KEY TITLE | |
| Key title | adverse events agents alveolar damage DAD alveolar hemorrhage amiodarone antineoplastic ARDS associated biological DMARDs biomarkers bleomycin bronchiolitis obliterans causative drug cells checkpoint inhibitors Chest X-ray chronic clinical manifestations corticosteroid cytotoxic developed differential diagnosis diffuse alveolar damage discontinuation DLI caused DLST DMARDs dose drug-induced interstitial pneumonia drug-induced lung injury EGFR EGFR-TKIs eosinophilic pneumonia erlotinib etanercept everolimus fatal gefitinib gemcitabine grade ground glass opacity herbal medicine histopathological HRCT hypersensitivity imaging findings immune checkpoint incidence induced lung injury infection infiltration infliximab interstitial lung disease Japan Japanese patients kinase inhibitors lesions lung cancer lung toxicity lymphocytes methotrexate monoclonal antibody nivolumab nonspecific NSCLC NSIP onset organizing pneumonia pathological patients with rheumatoid pattern phase Pleural effusion pneumocytes pneumonitis protein pulmonary edema pulmonary fibrosis Pulmonary hemorrhage radiological receptor reported Respir rheumatoid arthritis risk factors shows SP-A SP-D symptoms target antineoplastic drugs therapy treatment trial tumor tyrosine kinase |
| 245 ## - TITLE STATEMENT | |
| Title | Drug-Induced Lung Injury |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | First Department of Medicine Shinshu University School of Medicine Matsumoto, Nagano, Japan: |
| Name of publisher, distributor, etc. | Springer, |
| Date of publication, distribution, etc. | c2018 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 215 pages |
| Other physical details | Includes bibliographical references. |
| 490 ## - SERIES STATEMENT | |
| Series statement | Respiratory Disease Series: Diagnostic Tools and Disease Managements |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | This book covers various aspects of a respiratory system disorder associated with prescribed drugs that do not yet have established treatment guidelines, and for which the only treatment is to discontinue taking the drug. Very little clinical evidence regarding the disorder is available, since randomized trials cannot to be carried out, the onset of the disorder cannot be predicted, and the resulting pathological condition is life-threatening. However, the need for an established treatment continues to grow due to the introduction of many new drugs, such as anti-neoplastic drugs, biological products, and molecular target drugs, the adverse effects of which are difficult to differentiate from those of other lung diseases, such as lung infectious diseases.<br/>Drug-Induced Lung Injury offers a highly beneficial resource not only for respiratory physicians but also all medical clinicians who prescribe drugs, nurses, pharmacists and pharmaceutical scientists. Written by pioneering experts in the field, the book examines a wealth of cases and the insights they yield concerning the diagnosis, treatment and specific drugs causing the disease. It not only fosters a deeper understanding of the disorder but also highlights the current challenges and paves the way for future clinical research. |
| 600 ## - SUBJECT ADDED ENTRY--PERSONAL NAME | |
| General subdivision | Lungs -- Wounds and injuries |
| 9 (RLIN) | 43555 |
| General subdivision | Drugs -- Side effects |
| 9 (RLIN) | 43556 |
| General subdivision | Health & Fitness -- Diseases -- General |
| 9 (RLIN) | 32045 |
| General subdivision | Medical -- Clinical Medicine |
| 9 (RLIN) | 26816 |
| General subdivision | Medical -- Diseases |
| 9 (RLIN) | 28034 |
| General subdivision | Medical -- Evidence-Based Medicine |
| 9 (RLIN) | 32044 |
| General subdivision | Medical -- Internal Medicine |
| 9 (RLIN) | 26949 |
| General subdivision | Drugs -- Side effects |
| 9 (RLIN) | 43556 |
| General subdivision | Lungs -- Wounds and injuries |
| 9 (RLIN) | 43555 |
| General subdivision | Medicine & Public Health |
| 9 (RLIN) | 42899 |
| General subdivision | Pneumology/Respiratory System |
| 9 (RLIN) | 43557 |
| General subdivision | Medical › Pulmonary & Thoracic Medicine |
| 9 (RLIN) | 24000 |
| General subdivision | Medical / Clinical Medicine |
| 9 (RLIN) | 26816 |
| General subdivision | Medical / Pulmonary & Thoracic Medicine |
| 9 (RLIN) | 26869 |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 43558 |
| 9 (RLIN) | 43559 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | ddc |
| Koha item type | E-BOOKS |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Collection | Home library | Current library | Shelving location | Date acquired | Total checkouts | Full call number | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | 08/29/2022 | 616.2/4 HAN | EBS13145 | 08/30/2022 | 08/30/2022 | E-BOOKS |